Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia

Phase II study of PRO95780 plus rituximab in patients with relapsed follicular non-Hodgkin's lymphoma (NHL).

(2017) S. Wittebol et al.   JOURNAL OF CLINICAL ONCOLOGY

Effects of the antiangiogenic drug bevacizumab on tumor perfusion and drug delivery of 11C-labeled docetaxel in patients with non-small cell lung cancer (NSCLC): Implications for scheduling of antiangiogenic agents.

(2017) E. F. Smit et al.   JOURNAL OF CLINICAL ONCOLOGY

Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia

(2012) S. J. Conley et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Potent and sustained inhibition of HIF-1α and downstream genes by a polyethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effects

(2011) Puja Sapra et al.   ANGIOGENESIS

Antiangiogenic Therapy for Primary Liver Cancer: Correlation of Changes in Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Tissue Hypoxia Markers and Clinical Response

(2011) Adam C. Yopp et al.   ANNALS OF SURGICAL ONCOLOGY

Targeting SDF-1/CXCR4 to inhibit tumour vasculature for treatment of glioblastomas

(2011) D Tseng et al.   BRITISH JOURNAL OF CANCER

EMT: A new vision of hypoxia promoting cancer progression

(2011) Jian Jiang et al.   CANCER BIOLOGY & THERAPY

Vascular normalization: a real benefit?

(2011) Domenico Ribatti   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Glioblastoma Recurrence after Cediranib Therapy in Patients: Lack of "Rebound" Revascularization as Mode of Escape

(2011) E. di Tomaso et al.   CANCER RESEARCH

Targeting Tumor Hypoxia: Suppression of Breast Tumor Growth and Metastasis by Novel Carbonic Anhydrase IX Inhibitors

(2011) Y. Lou et al.   CANCER RESEARCH

VEGF and c-Met Blockade Amplify Angiogenesis Inhibition in Pancreatic Islet Cancer

(2011) W.-K. You et al.   CANCER RESEARCH

Antiangiogenic agents and HIF-1 inhibitors meet at the crossroads

(2011) Annamaria Rapisarda et al.   CELL CYCLE

Multihistology, Target-Driven Pilot Trial of Oral Topotecan as an Inhibitor of Hypoxia-Inducible Factor-1  in Advanced Solid Tumors

(2011) S. Kummar et al.   CLINICAL CANCER RESEARCH

Bevacizumab Has Differential and Dose-Dependent Effects on Glioma Blood Vessels and Tumor Cells

(2011) L. von Baumgarten et al.   CLINICAL CANCER RESEARCH

CXCL12 (SDF1 )-CXCR4/CXCR7 Pathway Inhibition: An Emerging Sensitizer for Anticancer Therapies?

(2011) D. G. Duda et al.   CLINICAL CANCER RESEARCH

Potential of CXCR4 antagonists for the treatment of metastatic lung cancer

(2011) Jan A Burger et al.   Expert Review of Anticancer Therapy

Antiangiogenic and Radiation Therapy

(2011) Ying Ren et al.   INVESTIGATIVE RADIOLOGY

Vandetanib Plus Pemetrexed for the Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer: A Randomized, Double-Blind Phase III Trial

(2011) Richard H. de Boer et al.   JOURNAL OF CLINICAL ONCOLOGY

RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

(2011) Adam M. Brufsky et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Trial of Vandetanib Compared With Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

(2011) Ronald B. Natale et al.   JOURNAL OF CLINICAL ONCOLOGY

RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

(2011) Nicholas J. Robert et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study

(2011) Atsushi Ohtsu et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular Imaging of Hypoxia

(2011) S. K. Chitneni et al.   JOURNAL OF NUCLEAR MEDICINE

Antiangiogenic therapy: impact on invasion, disease progression and metastasis

(2011) John M. L. Ebos et al.   Nature Reviews Clinical Oncology

Antiangiogenic therapy, hypoxia and metastasis: risky liaisons, or not?

(2011) Katrien De Bock et al.   Nature Reviews Clinical Oncology

Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases

(2011) Peter Carmeliet et al.   NATURE REVIEWS DRUG DISCOVERY

Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors

(2011) Eric Raymond et al.   NEW ENGLAND JOURNAL OF MEDICINE

Normalization of the Vasculature for Treatment of Cancer and Other Diseases

(2011) Shom Goel et al.   PHYSIOLOGICAL REVIEWS

Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma

(2011) Olivier Keunen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Targeting GLUT1 and the Warburg Effect in Renal Cell Carcinoma by Chemical Synthetic Lethality

(2011) D. A. Chan et al.   Science Translational Medicine

Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

(2010) M. Reck et al.   ANNALS OF ONCOLOGY

Identification of an Ire1alpha endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma

(2010) I. Papandreou et al.   BLOOD

Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer

(2010) Carlos H. Barrios et al.   BREAST CANCER RESEARCH AND TREATMENT

CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression

(2010) Xueqing Sun et al.   CANCER AND METASTASIS REVIEWS

HIF-2  Enhances  -Catenin/TCF-Driven Transcription by Interacting with  -Catenin

(2010) H. Choi et al.   CANCER RESEARCH

Aminoflavone, a Ligand of the Aryl Hydrocarbon Receptor, Inhibits HIF-1  Expression in an AhR-Independent Fashion

(2010) E. Terzuoli et al.   CANCER RESEARCH

Pharmacokinetic/Pharmacodynamic Modeling Identifies SN30000 and SN29751 as Tirapazamine Analogues with Improved Tissue Penetration and Hypoxic Cell Killing in Tumors

(2010) K. O. Hicks et al.   CLINICAL CANCER RESEARCH

CXCL12 (SDF-1)/CXCR4 Pathway in Cancer

(2010) B. A. Teicher et al.   CLINICAL CANCER RESEARCH

Targeting Hypoxic Cells through the DNA Damage Response

(2010) M. Olcina et al.   CLINICAL CANCER RESEARCH

Anticancer drugs that target metabolism: Is dichloroacetate the new paradigm?

(2010) Ioanna Papandreou et al.   INTERNATIONAL JOURNAL OF CANCER

Tumour hypoxia induces a metabolic shift causing acidosis: a common feature in cancer

(2010) Johanna Chiche et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice

(2010) Mitomu Kioi et al.   JOURNAL OF CLINICAL INVESTIGATION

Phase III Study of Carboplatin and Paclitaxel Alone or With Sorafenib in Advanced Non–Small-Cell Lung Cancer

(2010) Giorgio Scagliotti et al.   JOURNAL OF CLINICAL ONCOLOGY

Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)

(2010) Hedy Lee Kindler et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

(2010) David W. Miles et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival

(2010) Bernard Escudier et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206

(2010) Brian I. Rini et al.   JOURNAL OF CLINICAL ONCOLOGY

Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial

(2010) Cora N. Sternberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08

(2010) Carmen J. Allegra et al.   JOURNAL OF CLINICAL ONCOLOGY

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial

(2010) Roy S Herbst et al.   LANCET ONCOLOGY

Hypoxia-Inducible Factors and the Response to Hypoxic Stress

(2010) Amar J. Majmundar et al.   MOLECULAR CELL

Regulation of autophagy by ATF4 in response to severe hypoxia

(2010) T Rzymski et al.   ONCOGENE

Biomarkers of angiogenesis and their role in the development of VEGF inhibitors

(2009) N Murukesh et al.   BRITISH JOURNAL OF CANCER

Hypoxia-Induced Lysyl Oxidase Is a Critical Mediator of Bone Marrow Cell Recruitment to Form the Premetastatic Niche

(2009) Janine T. Erler et al.   CANCER CELL

Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis

(2009) John M.L. Ebos et al.   CANCER CELL

Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis

(2009) Marta Pàez-Ribes et al.   CANCER CELL

Imaging the Unfolded Protein Response in Primary Tumors Reveals Microenvironments with Metabolic Variations that Predict Tumor Growth

(2009) M. T. Spiotto et al.   CANCER RESEARCH

Marked Activity of Irinotecan and Rapamycin Combination toward Colon Cancer Cells In vivo and In vitro Is Mediated through Cooperative Modulation of the Mammalian Target of Rapamycin/Hypoxia-Inducible Factor-1  Axis

(2009) E. Pencreach et al.   CLINICAL CANCER RESEARCH

Regulation of Autophagy Through Multiple Independent Hypoxic Signaling Pathways

(2009) Kasper Rouschop et al.   CURRENT MOLECULAR MEDICINE

HIF-1: upstream and downstream of cancer metabolism

(2009) Gregg L Semenza   CURRENT OPINION IN GENETICS & DEVELOPMENT

Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies

(2009) Annamaria Rapisarda et al.   DRUG RESISTANCE UPDATES

Molecular imaging of hypoxia with radiolabelled agents

(2009) Gilles Mees et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Glucose deprivation-induced metabolic oxidative stress and cancer therapy

(2009) DouglasR Spitz et al.   Journal of Cancer Research and Therapeutics

Hypoxia-inducible factors in stem cells and cancer

(2009) Jolly Mazumdar et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Development of HIF-1 inhibitors for cancer therapy

(2009) Barbara Onnis et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

The unfolded protein response protects human tumor cells during hypoxia through regulation of the autophagy genes MAP1LC3B and ATG5

(2009) Kasper M.A. Rouschop et al.   JOURNAL OF CLINICAL INVESTIGATION

Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer

(2009) Eric Van Cutsem et al.   JOURNAL OF CLINICAL ONCOLOGY

Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

(2009) Bernard Escudier et al.   JOURNAL OF CLINICAL ONCOLOGY

Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

(2009) Robert J. Motzer et al.   JOURNAL OF CLINICAL ONCOLOGY

Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition

(2009) A. Rapisarda et al.   MOLECULAR CANCER THERAPEUTICS

Differential effects of the vascular endothelial growth factor receptor inhibitor PTK787/ZK222584 on tumor angiogenesis and tumor lymphangiogenesis

(2009) T. Schomber et al.   MOLECULAR CANCER THERAPEUTICS

Avastin-Tarceva combination fails in lung cancer

(2009) Dan Jones   NATURE BIOTECHNOLOGY

Pazopanib

(2009) Ronald M. Bukowski et al.   NATURE REVIEWS DRUG DISCOVERY

Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer

(2009) Jolien Tol et al.   NEW ENGLAND JOURNAL OF MEDICINE

Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics

(2009) G L Semenza   ONCOGENE

FDA Drug Approval Summary: Bevacizumab (Avastin(R)) as Treatment of Recurrent Glioblastoma Multiforme

(2009) M. H. Cohen et al.   ONCOLOGIST

Human cancers converge at the HIF-2α oncogenic axis

(2009) Aleksandra Franovic et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells

(2009) K. Lee et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Hypoxia-Inducible Factor-1 Target Genes as Indicators of Tumor Vessel Response to Vascular Endothelial Growth Factor Inhibition

(2008) D. T. Dang et al.   CANCER RESEARCH

Homologous Recombination Is the Principal Pathway for the Repair of DNA Damage Induced by Tirapazamine in Mammalian Cells

(2008) J. W. Evans et al.   CANCER RESEARCH

Preferential Cytotoxicity of Bortezomib toward Hypoxic Tumor Cells via Overactivation of Endoplasmic Reticulum Stress Pathways

(2008) D. R. Fels et al.   CANCER RESEARCH

Glycolytic enzyme inhibitors in cancer treatment

(2008) Roberto Scatena et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study

(2008) Leonard B. Saltz et al.   JOURNAL OF CLINICAL ONCOLOGY

A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer

(2008) J. Randolph Hecht et al.   JOURNAL OF CLINICAL ONCOLOGY

Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival

(2008) Ashwatha Narayana et al.   JOURNAL OF NEUROSURGERY

Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1 

(2008) M. Y. Koh et al.   MOLECULAR CANCER THERAPEUTICS

Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib

(2008) T. P. Padera et al.   MOLECULAR CANCER THERAPEUTICS

A RNA antagonist of hypoxia-inducible factor-1 , EZN-2968, inhibits tumor cell growth

(2008) L. M. Greenberger et al.   MOLECULAR CANCER THERAPEUTICS

Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence

(2008) A. D. Norden et al.   NEUROLOGY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor Angiogenesis

(2008) Robert S. Kerbel   NEW ENGLAND JOURNAL OF MEDICINE